Candida-specific helper T cells are preferential and early targets of HIV

June 09, 2016

Candida yeasts normally live on human skin and mucous membranes without causing disease. In individuals with a weakened immune system, however, they are a major cause of opportunistic infections. A study published on June 9th in PLOS Pathogens shows how HIV soon after infection specifically targets and destroys the very immune cells that keep Candida in check.

Opportunistic infections--clinically relevant diseases caused by usually harmless microbes--are a hallmark of HIV/AIDS and thought to be caused by a progressively weakening immune system that loses the ability to suppress even known pathogens. It is known that CD4 helper T cells, the primary target of HIV, are a key part of the immune response to many opportunistic microbes. However, HIV-positive individuals do not suddenly become susceptible to all sorts of infections. Instead, there is a consistent sequence in the vulnerability to different opportunistic pathogens during the progression of HIV-infected individuals to AIDS.

Haitao Hu, from the University of Texas Medical Branch in Galveston, USA, and colleagues, are interested in the reasons for this differential vulnerability, including the question why the common opportunistic infections with Candidaalbicans occur early during HIV/AIDS progression. The researchers had previously discovered that human C. albicans-specific CD4 helper T cells are more permissive to HIV infection in vitro compared to CD4 helper T cells specific for cytomegalovirus (CMV), another opportunistic pathogen but one that usually causes disease at late stages of HIV/AIDS.

In this study, they examine how HIV targets these two groups of pathogen-specific CD4 T-cells in HIV-infected individuals over time. The researchers used consecutive blood samples from 20 HIV-infected individuals who had C. albicans-specific and CMV-specific CD4 helper T cells, experienced progressive loss of overall numbers of CD4 helper T cells over time, and who had not yet started antiretroviral treatment (ART). Compared to CMV-specific cells, the researchers found, C. albicans-specific CD4 T cells were more susceptible to HIV in vivo and preferentially depleted earlier in the HIV-infected individuals.

It is known that C. albicans-specific CD4 T helper cells come in two different 'flavors'. Some of them produce mainly two immune stimulators called IL-17 and IL-22 (and are referred to as Th17 cells), whereas others, so-called Th1 cells, produce predominantly interferons, another type of immune signaling molecule. In the HIV-infected individuals, the researchers saw a sequential dysfunction for C. albicans-specific CD4 T cell response, with an earlier and more profound depletion of Th17 cells. This suggests that these Th17 cells are the ones that primarily prevent C. albicans from causing disease in healthy individuals.

"Based on an ART naïve HIV infection cohort", the authors summarize, "we comparatively investigated the dynamic impact of HIV on C. albicans- and CMV specific CD4 T-cell immunity in HIV non-controllers. We identified a sequential dysfunction and preferential depletion of C. albicans-specific CD4 T cell response during progressive HIV infection". Their results, they suggest, "may provide an immunological basis for early loss of immune control over mucosal candidiasis in HIV-infected individuals and also suggest a potential mechanism for pathogen-specific immune failure in AIDS".
In your coverage please use this URL to provide access to the freely available article in PLOS Pathogens:

Please contact if you would like more information.

Funding: The work was supported by National Institutes of Health Grant 1R21AI110214 (to HH) ( and the Robert Mapplethorpe Foundation grant (to HH) ( The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Liu F, Fan X, Auclair S, Ferguson M, Sun J, Soong L, et al. (2016) Sequential Dysfunction and Progressive Depletion of Candidaalbicans-Specific CD4 T Cell Response in HIV-1 Infection. PLoS Pathog 12(6): e1005663. doi:10.1371/journal.ppat.1005663


Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to